Filing Flows › Industries › Services-Medical Laboratories › Capital spending and supply chain
Services-Medical Laboratories: capital spending and supply chain
SIC 8071 · 18 companies with filed cash-flow statements
Analysis
18 companies in Services-Medical Laboratories (SIC 8071) spent $1.7B on capital projects over their latest twelve months, 41% of the $4.1B their operations generated; the three largest spenders — DGX, LH, RDNT — account for 79%.
Capital spending is 4.3% of the industry's $39.3B of annual revenue.
By the industry's asset mix most of it goes to equipment (54%); about $307M is imported.
The largest supplier of that spending is health care structures ($409M).
Its largest supplying industries, by the input-output tables: imports ($3.2B), drugs and druggists' sundries ($1.6B), biological product (except diagnostic) manufacturing ($1.4B).
Charts
Capital spending by company
| Company | Capital spending | Operating cash flow | Capex / OCF | Period |
|---|---|---|---|---|
| DGX Quest Diagnostics | $576M | $2.0B | 30% | TTM to Q3 2026 |
| LH Labcorp Holdings | $528M | $1.8B | 29% | TTM to Q3 2026 |
| RDNT RadNet | $238M | $310M | 77% | TTM to Q2 2026 |
| NTRA Natera | $160M | $213M | 75% | TTM to Q3 2026 |
| GH Guardant Health | $58.7M | −$173M | — | TTM to Q3 2026 |
| CSTL Castle Biosciences | $35.8M | $39.7M | 90% | TTM to Q3 2026 |
| FTRE Fortrea Holdings | $32.8M | $202M | 16% | TTM to Q3 2026 |
| FLGT Fulgent Genetics | $15.8M | $14.4M | 110% | TTM to Q3 2026 |
| BLLN BillionToOne | $14.0M | $47.9M | 29% | TTM to Q3 2026 |
| VCYT Veracyte | $11.9M | $174M | 7% | TTM to Q3 2026 |
| PSNL Personalis | $10.1M | −$97.6M | — | TTM to Q3 2026 |
| GRAL Grail | $5.8M | −$306M | — | TTM to Q3 2026 |
| AMS American Shared Hospital Services | $1.8M | $5.4M | 34% | TTM to Q2 2026 |
| XGN Exagen | $1.1M | −$6.5M | — | TTM to Q2 2026 |
| BDSX Biodesix | $919K | −$18.2M | — | TTM to Q3 2026 |
| SERA Sera Prognostics | $488K | −$28.5M | — | TTM to Q3 2026 |
| ACON Aclarion | $16K | −$8.9M | — | TTM to Q3 2026 |
| BGLC BioNexus Gene Lab | $7K | −$847K | — | TTM to Q2 2026 |
Customers and suppliers named in annual reports
| Supplier | Customer | Share of supplier revenue | Evidence | Source |
|---|---|---|---|---|
| DGX | Medicare & Medicaid | 8% | Stated in 10-K (sentence) | filing |
| CAI | Medicare & Medicaid | 39% | Stated in 10-K (sentence) | filing |
| NTRA | Medicare & Medicaid | 13% | Stated in 10-K (sentence) | filing |
| VCYT | Medicare & Medicaid | 34% | Stated in 10-K (sentence) | filing |
| CDNA | Medicare & Medicaid | 46% | Stated in 10-K (sentence) | filing |
| BDSX | Medicare & Medicaid | 32% | Stated in 10-K (sentence) | filing |
| XGN | Medicare & Medicaid | 24% | Stated in 10-K (sentence) | filing |
| PSNL | MRNA | 22% | Stated in 10-K (XBRL) | filing |
| RDNT | U.S. government | — | Stated in 10-K (named, share not stated) | filing |
| RDNT | Medicare & Medicaid | — | Stated in 10-K (named, share not stated) | filing |
| TMO | CDNA | — | Stated in 10-K (named, share not stated) | filing |
| ILMN | NTRA | — | Stated in 10-K (named, share not stated) | filing |
| ILMN | GH | — | Stated in 10-K (named, share not stated) | filing |
| ILMN | FLGT | — | Stated in 10-K (named, share not stated) | filing |
| ILMN | GRAL | — | Stated in 10-K (named, share not stated) | filing |
| ILMN | CAI | — | Stated in 10-K (named, share not stated) | filing |
| TWST | GRAL | — | Stated in 10-K (named, share not stated) | filing |
The interactive money flow: switch views, follow each dollar →
Evidence grades: A filed figure · B computed from filed figures · C industry average (BEA input-output and fixed-asset tables) applied to filed figures. Estimates are not the companies’ own records. Not investment advice.